ADAPTIVE BIOTECHNOLOGIES CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 68.60% for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-03.
Discontinued › Notes › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2021-11-03
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2021-03-31 was 68.20%, a 3.54% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2020-03-31 was 70.70%, a 9.78% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2019-03-31 was 64.40%.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2020 was 71.40%, a 4.85% increase from fiscal 2019.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2019 was 68.10%, a 0.00% change from fiscal 2018.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2018 was 68.10%, a 2.99% decline from fiscal 2017.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2017 was 70.20%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 12 month |
|---|---|---|---|---|
| 2021-09-30 | 68.60% 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | 68.30% 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | 68.20% 10-Q · filed 2021-05-05 | |||
| 2020-12-31 | 71.40% 10-K · filed 2021-02-24 | |||
| 2020-09-30 | 71.20% 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | 71.00% 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | 70.70% 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | 68.10% 10-K · filed 2021-02-24 | |||
| 2019-09-30 | 68.00% 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | 67.90% 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | 64.40% 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | 68.10% 10-K · filed 2021-02-24 | |||
| 2017-12-31 | 70.20% 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |